Although the role of HDAC3 selective inhibitors in treating renal fibrosis has been explored and appears to be a viable option, their potential role in AKI and the underlying mechanism are yet to be determined (Sato and Yanagita, 2018). The gene discussed is HDAC3; the disease is acute kidney injury.